Anne Marie Simon Barfoed – Page 2 – Sound Bioventures

All Events Fund articles Fund PR News Portfolio articles Portfolio PR

From Doctor To Investor: How My MBA Kickstarted An Exciting Career In Life Sciences Venture Capital

Aiming to make an impact in his career, certified medical doctor Philip Brainin combined his healthcare expertise with an MBA to launch a career in life sciences venture capital A keen interest in learning and a desire to help others have defined Philip Brainin’s career so far. Today he is an analyst with a specialist […]

Sound Bioventures appoints Fredrik Lehmann as its first Entrepreneur-in-Residence

Stockholm, Sweden and Cambridge, MA, USA – 13 October 2023 – Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced that Fredrik Lehmann, Ph.D., MBA has joined the company as its first Entrepreneur-in-Residence. Fr ...

At the intersection of entrepreneurship, life science, & patient needs

Fredrik Lehmann, Entrepreneur in Residence at Sound Bioventures, explains how success in life science takes tenacity and constant focus on patient needs.

Bringing everything together for an autoimmunity game changer

At AbolerIS Pharma, it’s all about creating balance. The Belgian/French biotech company is gearing up for clinical trials of a novel therapy for stabilizing chaotic immune systems. As CEO Ann Meulemans explains, it requires finding the right interplay between management’s industry experience and passion, cutting-edge science from company foun ...

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-based mechanism that acts upstream of current anti-inflammatory standard of care drugs in autoimmune diseases such as rheumatoid arthritis. Proceeds will be ...

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

25 July 2023 Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage bioph ...

Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases

Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Developed for Once Daily Oral Dosing to Address Autoimmune Diseases by Providing Immunomodulation without Immunosuppression Cambridge, Mass., June 1, 2023 – Artax ...

Reaching the next level of creating novel therapies for genetic diseases

ARTHEx Biotech is entering a new phase in its development of breakthrough treatments for genetically-driven disorders. It’s set to begin the first clinical trials for one of its microRNA modulators as a therapeutic approach for the degenerative muscular disease myotonic dystrophy type 1.[1] Yet according to Dr. Frédéric Legros, the company’s ...

VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trial

Leiden, The Netherlands, 25 May 2023 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round. The round was led by Sound Bioventures whilst the European Innovation Council (EIC) Fund ...

Combining instinct & freedom to support startups

Casper Breum says he can usually tell early on if a startup will be a good fit for investment. As a founding partner at Sound Bioventures, Breum is involved in reviewing the roughly six hundred investor pitches from biotech companies the firm evaluates each year. His predictive ability was honed throughout his career, which he […]

We are excited to welcome Arthex to our portfolio

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM1, is expected to initiate in 2H2023 Round led by Columbus Venture Partners, with participation of European Innovation Council (EIC), Hadean Ventures, Sound ...

Breye Therapeutics Strengthens Management Team and Board

“We are thrilled to welcome Peter as CSO. His extensive experience in ophthalmology drug development will be invaluable as we advance our lead compound through clinical development. Gabriela’s appointment to the Board brings significant industry and development experience which will be instrumental as we build a pipeline of novel oral therapies for ...